The human APOBEC3G (A3G) is a potent inhibitor of HIV-1 replication and its activity is suppressed by HIV-1 virion infectivity factor (Vif). Vif neutralizes A3G mainly by inducing its degradation in the proteasome and blocking its incorporation into HIV-1 virions. Assessing the time needed for A3G incorporation into virions is, therefore, important to determine how quickly Vif must act to induce its degradation. We show that modelling the intracellular half-life of A3G can induce its Vif-independent targeting to the ubiquitinproteasome system. By using various amino acids (X) in a cleavable ubiquitin-X-A3G fusion, we demonstrate that the half-life (t1/2) of X-A3G can be manipulated. We show that A3G molecules with a half-life of 13 min are incorporated into virions, whereas those with a half-life shorter than 5 min were not. The amount of X-A3G incorporated into virions increases from 13 min (Phe-A3G) to 85 min (Asn-A3G) and remains constant after this time period. Interestingly, despite the presence of similar levels of Arg-A3G (t1/2 = 28 min) and Asp-A3G (t1/2 = 65 min) into HIV-1 Δvif virions, inhibition of viral infectivity was only evident in the presence of A3G proteins with a longer half-life (t1/2 ≥ 65 min).
Introduction
The human apolipoprotein B mRNA-editing enzyme, APOBEC3G (A3G), is a potent host antiretroviral enzyme that can restrict HIV-1 infection by two known mechanisms. First, A3G is incorporated into HIV-1 virions during viral production and subsequently induces hypermutation of viral cDNA through cytidine deamination of newly synthesized reverse transcripts (Mariani et al., 2003; Soros et al., 2007; Stopak et al., 2003; Suspene et al., 2004; Yu et al., 2004a; Xu et al., 2007) . This mode of action is counteracted by HIV-1 Vif that prevents incorporation of A3G into virions. The viral protein acts predominantly by forming a Cul5-E3 ubiquitin ligase complex that target these proteins for degradation by the ubiquitin-proteasome pathway (Conticello et al., 2003; Liu et al., 2005; Marin et al., 2003; Mehle et al., 2004a Mehle et al., , 2004b Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2004b Yu et al., , 2003 . Second, cellular A3G can function as a potent post-entry restriction factor for HIV-1 during reverse transcription in resting CD4 + T cells (Chiu et al., 2005) .
It was recently proposed that polyubiquitinated Vif could function as a vehicle to transport A3G for proteasome degradation . It has been shown that Vif is polyubiquitinated and subject to proteasome degradation without A3G (Akari et al., 2004; Mehle et al., 2004a) , and this reaction is catalyzed by the same Cul5-E3 ligase complex (Mehle et al., 2004b) . Thus, the mechanism by which Vif destabilizes A3G and mediates its degradation is still under debate.
Cellular proteases mediate protein degradation, which vary from small proteins such as extracellular trypsin and intracellular caspases, to large, ATP-dependent proteases that mediate the destruction of ubiquitin-protein conjugates called the 26S proteasome (Baumeister et al., 1998) .
Intracellular protein degradation involves ubiquitin conjugation (Ciechanover et al., 1978; Hershko et al., 1980 Hershko et al., , 1983 and the selectivity of this conjugation is determined by specific degradation signals (degrons) in short-lived proteins (Bachmair et al., 1986; Bachmair and Varshavsky, 1989; Chau et al., 1989; Johnson et al., 1990; Bartel et al., 1990) . Ubiquitin-dependent processes play a major role in cellular physiology (Finley et al., 1984; Jentsch et al., 1987; Finley et al., 1987; Goebl et al., 1988; Finley et al., 1989; Hochstrasser and Varshavsky, 1990; Hochstrasser et al., 1991) , primarily by controlling the levels of intracellular protein.
Metabolic instability of short-lived proteins allows for efficient temporal control of their intracellular concentrations and was shown to be essential for the regulatory functions of several eukaryotic and bacterial proteins (Nasmyth, 1983; Banuett et al., 1986; Bahl et al., 1987) . Many other proteins, while long-lived as components of larger macromolecular complexes such as ribosomes and oligomeric proteins are metabolically unstable in a free, unassociated state (Maicas et al., 1988; Tsay et al., 1988) .
In this study, we decided to manipulate the cytoplasmic half-life of A3G protein to allow for an efficient control of its intracellular concentration. By doing this, we sought to understand how A3G halflife can influence its antiviral activity independently of Vif. To achieve this aim, we have adapted the ubiquitin-fusion technique, first described by Varshavsky et al. (Bachmair et al., 1986) . This strategy relates the intracellular half-life of a protein to the identity of its Nterminal residue. This method involves the fusion of an ubiquitin monomeric moiety immediately adjacent to the N-terminal amino acid of a protein, which here results in an ubiquitin-A3G fusion protein.
Fusions to Ub are co-translationally cleaved at the Ub-protein junction by specific proteases. This approach allowed replacing the first amino acid sequence of A3G (ATG) by any desired amino acid described by the N-end rule (Baker 1996; Varshavsky 1996) . The set of individual amino acids introduced at the N-terminus of A3G has been previously classified according to the half-life they confer to the protein (Bachmair et al., 1986; Bachmair and Varshavsky, 1989; Gonda et al., 1989; Kwon et al., 1998; Tasaki et al., 2005; Varshavsky, 1996) . They encompass four classes of amino acids in the N-end rule: primary (Leu, Phe, and Arg), secondary (Asp), tertiary (Asn), and stabilizing (Met and Gly) residues. Primary residues are the least stables amino acids (Varshavsky, 1996) . In this study, wt A3G maintains Met at its N-terminus.
Using this strategy we were able to destabilize the intracellular A3G molecules, mimicking the effect of Vif on A3G steady-state. This approach allowed monitoring the intracellular activity of A3G in a Viffree environment. By reducing the half-life of each A3G protein we showed that incorporation into viral particles occurs shortly after A3G synthesis (t1/2 = 13 min). Interestingly, similar levels of Arg-A3G (t1/2 = 28 min) and Asp (t1/2 = 65 min) were detected into HIV-1 virions. However, inhibition of viral infectivity is only detected in the presence of A3G proteins with a longer half-life (t1/2 ≥ 65 min).
Results

Modulation of APOBEC3G half-life by the N-end rule pathway
We sought to manipulate the half-life of A3G to assess whether the quantity of protein correlates with viral incorporation and antiviral infectivity. With this goal in mind, we expressed A3G proteins with a dissimilar intracellular half-life. Mechanistically, the system is based on deubiquitylating enzymes that potently and rapidly cleave the junction between the C-terminus of ubiquitin and the N-terminus of a fused protein domain, in a process called deubiquitination. Thus, we fused the coding sequence for human Ub with A3G to generate Ub-X-A3G, where X represents any class of amino acids described by the N-end rule. According to the identity of the amino acid used at Nterminus, this arrangement allowed us to obtain A3G variants with different half-lives. In this study, we used a panel of seven different amino acids that have been described as involved in the N-end rule pathway (Bachmair et al., 1986; Gonda et al., 1989; Varshavsky, 1996) . The schematic representation of the EGFP-IRES-Ub-X-A3G fusion construct and the amino acids used at the N-terminus of A3G is represented in Fig. 1 .
Vif has been proposed to target A3G for accelerated degradation in the 26S proteasome via the ubiquitin-proteasome pathway (Conticello et al., 2003; Liu et al., 2005; Marin et al., 2003; Mehle et al., 2004a Mehle et al., , 2004b Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2004b Yu et al., , 2003 . A similar situation occurs with the N-end rule substrates that are bound by a targeting complex, followed by formation of a substrate-linked multi-Ub chain. The ubiquitylated substrate is processively degraded by the 26S proteasome. To determine whether Ub-X-A3G follows the 26S proteasome degradation pathway Fig. 1 . Schematic representation of A3G bicistronic expression vector (pEGFP⁎IRES-Ub-X-A3G-HA). Transcription of the mRNA is initiated at the cytomegalovirus promoter/ enhancer upstream of the EGFP coding sequence. The translation start and stop codon for EGFP and Ub-X-A3G is shown. The site for the post-translational cleavage between Ub and X-A3G is shown with a downward arrow. EGFP protein was used with a standardization purpose as an internal control for the synthesis of the EGFP-IRES-Ub-X-A3G transcript. This was achieved by the presence of an internal ribosomal entry site (IRES), which allows the creation of a bicistronic transcription unit, in which EGFP and Ub-X-A3G sequences will be translated independently. The amino acid residues used in this study are indicated, which in eukaryotes are classified as stabilizing and destabilizing, according to the half-life that they confer to the protein (Varshavsky, 1996) . Fig. 2 . Expression of A3G mutants. (A) Wild-type A3G and N-terminal A3G mutants are shown above as WT, Met, Gly, Asn, Asp, Arg, Phe, and Leu. EGFP expression is shown as a control for the transfection. GAPDH is shown as a general control to the quantity of protein loading in Western blotting. Briefly, 2 μg of each plasmid was used to transfect 293T cells in 6-well plates. 40-44 h after transfection cells were washed twice with room-temperature PBS and lysed in cold RIPA lysis buffer. Lysates were subjected to WB analysis. (B) The stability of A3G variants is regulated by the proteasome. 293T cells were transfected with equal amounts of Ub-Arg-A3G, Ub-Phe-A3G and Ub-Leu-A3G isogenic plasmids. 36 h after transfection, cells were treated with proteasome inhibitor MG-132 (20 μM) for 4 h and analyzed by SDS-PAGE after lysis. The blots were probed with anti-HA antibody, stripped, and reprobed with anti-EGFP or anti-GAPDH antibody. The intensity of Arg-A3G, Phe-A3G and Leu-A3G bands increases with proteasome inhibitor MG132 showing that degradation of these proteins will not occur. These results confirm that Arg-A3G, Phe-A3G and Leu-A3G are expressed but with low steady-state. Fig. 3 . Cycloheximide chase analysis. A3G WT and N-terminal A3G variants were expressed in 293T cells (60-mm plates) and, the second day after transfection the cells were split in 6-well plates and the translation inhibitor cycloheximide (100 μg/ml) was added to each of the cell cultures. 293T cells expressing A3GWT, Met-A3G, and Gly-A3G were incubated with cycloheximide for 1, 2, 3, and 4 h; for Asn-A3G and Asp-A3G expression were incubated 1, 2, and 3 h; for Arg-A3G and Phe-A3G expression were incubated 20, 40, and 60 min, and 5, 10, and 20 min for Leu-A3G. The zero time-point received drug-free diluent DMSO. Cellular lysates were obtained at each time-point and the protein content was analyzed by WB using the anti-HA HRP-conjugated monoclonal antibody (Roche). α-GAPDH antibody was used as a loading control. Above each western-blot, the mean relative value of band density (INT/mm 2 ) from three independent experiments was plotted against time. A linear regression line was drawn through the data points and was used to calculate the half-life value of each protein, which is shown between brackets.
in the absence of HIV-1 Vif protein, we replaced the first amino acid in A3G sequence by six different residues.
Methionine at the N-terminus of A3G sequence was used as a control for expression of wild-type deaminase in this system. The corresponding recombinant plasmids EGFP-IRES-Ub-X-A3G are isogenic except for the sequence of the first amino acid of A3G. To determine the half-life of the different A3G constructs we transfected equal amounts of different Ub-X-A3G plasmids in 293T cells. The expression profiles obtained for the different A3G variants showed that the proteins containing stable residues (Met and Gly), tertiary residue (Asn) and secondary residue (Asp) have higher expression levels than those having the least stable residues (Arg, Phe and Leu) ( Fig. 2A) . This vector was designed to have the coding sequence of the EGFP under the control of the cytomegalovirus promoter, along with an internal ribosomal entry site (IRES) upstream of the Ub-X-A3G sequence. This arrangement allows expression of EGFP independently of A3G. Therefore, while A3G expression should be different according to amino acid present at the N-terminus, EGFP levels should remain similar for all the constructs allowing us to monitor the efficiency of DNA transfection.
As seen in Fig. 2A , the molecular weight of different X-A3G proteins was similar to the wild-type deaminase showing that ubiquitin (Ub) was cleaved off from A3G. In addition, GAPDH control shows that these differences regarding Ub-X-A3G expression were not due to protein loading. To discard a possible toxicity effect due to the chimeric A3G expression, a cell viability assay was performed using the tetrazolium salt WST-1 (Roche), which showed that the differences observed were not due to abnormal cell physiology (data not shown).
The half-life of the least stable proteins (Arg-A3G, Phe-A3G and Leu-A3G) was significantly higher when the transfected cell cultures were treated with proteasome inhibitor, MG132. With this inhibitor the steady-state of X-A3G proteins increase and the corresponding bands appear stronger in the western-blot. As shown in Fig. 2B , Arg-A3G, Phe-A3G, and Leu-A3G proteins were barely evident without inhibitor. These results show that our A3G constructs are physiological substrates of the ubiquitin-proteasome degradation pathway, and the lower level of expression detected for Arg-A3G, Phe-A3G and Leu-A3G was indeed a consequence of the amino-terminal destabilizing residue.
Kinetics of the in vivo degradation of A3G variants
The observation that A3G is incorporated into the virion core suggests several sources of the deaminase. Most likely, the mechanism of A3G virion incorporation depends on the amount of deaminase present in the cytoplasm capable to be targeted into the virion. One important variable for this mechanism is the required time for its recruitment into the virion core. It is conceivable that A3G cannot be readily rescued for virion incorporation when it is bound to the cellular high molecular mass (HMM) complex. Therefore, fine-tuning A3G half-lives can help to understand the time-space relationship of A3G targeting to the viral particle. The N-end rule should then provide an efficient temporal control of A3G intracellular concentration.
To assess whether the different A3G constructs could be used with this intention, we carried out a cycloheximide chase analysis to monitor the in vivo decay of A3G proteins. We used this approach, instead of pulse-chase analysis, because we aimed to monitor the turnover of existing proteins and to examine newly synthesized molecules. In addition, due to the expected rapid degradation of our least stable proteins, those proteins could only be detected by this method if the pulse-labeling and chase-times were very short (less than 5 min).
By treating cells with cycloheximide we showed that the in vivo half-life of the different A3G proteins varied from less than 5 min to more than 4 h, depending on the nature of the amino acid residue present at the amino-terminus of A3G (Fig. 3) . Specifically, deubiquitinated A3G proteins with either Met or Gly at the amino-terminus displayed a relatively long half-life of more than 4 h, similar to the halflife of control A3G WT. In contrast, A3G variants bearing N-terminal destabilizing residues classified as primary amino acids exhibited very short half-lives. Cycloheximide chase analysis showed that the half-life of Arg-A3G was about 28 min, b20 min for Phe-A3G and less than 5 min for Leu-A3G. In addition, the half-life of A3G proteins bearing aminoterminal residues Asn and Asp was approximately 85 min and 65 min, respectively.
Amino-terminal A3G variants are targeted to degradation by HIV-1 Vif protein
Due to the mechanism of the N-end rule, it was conceivable that X-A3G variants could somehow escape the action of Vif by a different pathway of degradation. It could result that the alteration of the first N-terminal residue in A3G may have affected its subcellular distribution allowing the protein to escape the action of Vif. In this way, and according to the fact that wild-type A3G stability is impaired in the presence of Vif protein (Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003) , we sought to determine if our A3G constructs were targeted for degradation by Vif in a similar manner. Basing on the expression profiles obtained for the different proteins, those with a longer half-life (Met-A3G, Gly-A3G, Asn-A3G, and Asp-A3G) were expressed in 293T cells in the presence of Vif (Fig. 4) .
Although all A3G variants were degraded in the proteasome in a Vif-independent manner, the results obtained showed that they were also targeted by Vif (Fig. 4) . Even with a lower half-life, protein quantity of the three least stable constructs (Arg-A3G, Phe-A3G, and Leu-A3G) was also reduced by Vif (data not shown) showing that Vif binds A3G shortly after its synthesis. These results also show that Ub-X-A3G fusions and its cleavage products do not have deleterious affects on deaminase folding, being capable of targeted degradation by Vif. Moreover, in an in vitro deamination assay all A3G constructs Fig. 4 . Detection of X-A3G proteins in the presence of Vif. 293T cells were cotransfected in a 6-well plate with 1 μg of Ub-Met-A3G, Ub-Gly-A3G, Ub-Asn-A3G, and Ub-Asp-A3G, and 1 μg of pcDNA-Vif. 40-44 h after transfection, cells were lysed and protein content was analyzed by SDS-PAGE.
were able to deaminate a synthetic ss-deoxyoligonucleotide harboring a target sequence for A3G deamination, showing that A3G fusions to Ub did not affect the catalytic activity of the different variants (Supplementary data). Nevertheless, caution should be taken when interpreting these results since deamination assays were nonquantitative. 
Virion incorporation and antiviral activity of N-terminal A3G variants
In this study we sought to investigate how A3G half-life can influence its antiviral activity. We first asked whether the least stable A3G proteins were able to inhibit HIV-1 infection without Vif. Viral stocks were produced by transfection of pNL4.3Δvif into 293T cells, with equal amounts of A3G WT or N-terminal A3G variants. We also transfected A3G in the presence of pNL4.3WT plasmid to compare the infectivity of viruses produced in the presence of Vif. Two days after transfection, virions were harvested and, after normalization for p24 concentration, were used to infect HeLa P4 cells (Figs. 5A, B) . The remaining HIV-1Δvif viral stock was used for the detection of A3G into virions (Fig. 5C ). Analysis HIV-1Δvif virions revealed the presence of A3G (Phe-A3G) 13 min after its synthesis (Fig. 5C, lane 7) . In contrast, A3G with a half-life of 5 min (Leu-A3G) was absent from all the virions analyzed (Fig. 5C, lane 8) . As seen in Fig. 5D , the amount of A3G incorporated into virions increases from 13 (Phe-A3G) to 85 min (Asn-A3G), remaining relatively constant after this period of time.
In regard to this observation, we hypothesized that viral infectivity could be reduced similarly. This hypothesis stem from the assumption that the presence of A3G into virions is sufficient and necessary to influence its antiviral activity. Therefore, to examine if A3G variants were active against HIV-1Δvif viruses, we tested all our isogenic proteins for their ability to inhibit viral infectivity (Fig. 5A ). As expected, A3G proteins bearing N-terminal stabilizing amino acids (Met and Gly) inhibited HIV-1Δvif infection comparably to A3G WT (Fig. 5A) . Surprisingly, A3G proteins bearing secondary (Asp) and tertiary (Asn) amino-terminal residues also exhibited antiviral activities similar to A3G WT (Fig. 5A) . Initially, we expected a reduction in the antiviral activity of these A3G variants, since Asn-A3G and Asp-A3G are considered destabilizing residues with lower halflives. Nonetheless, the total amount of Asn-A3G and Asp-A3G in the cell at 85 and 65 min, respectively, was sufficient to be incorporated into virions and inhibit HIV-1Δvif infection to a level similar to wildtype protein (Fig. 5A) . In contrast, the ability of Arg-A3G and Phe-A3G to inhibit HIV-1Δvif infectivity was greatly impaired when compared to the more stable proteins (Fig. 5A) . As expected, Leu-A3G (t1/ 2 = 5 min) did not display any antiviral effect in the absence of Vif (Fig. 5A) . Interestingly, similar incorporation levels of A3G proteins displaying different half-lives (Asp-A3G and Arg-A3G) (Fig. 5C , lanes 5 and 6) did not result in a similar inhibition of HIV-1Δvif infection (Fig. 5A ). When we determined the infectivity of wild-type viruses (Fig. 5B) , the variations observed among the virions produced in the presence of the different A3G proteins, were not significant (p N 0.05).
Finally, we decided to dilute wild-type A3G to levels comparable to those observed with Phe-A3G, and compare the ability to inhibit HIV1Δvif infection. As seen in Fig. 5E (lower panel), when we reduced by 10-fold the amount of A3G WT transfected, we obtained a level of expression comparable to Phe-A3G (Fig. 5E, compare lanes 1 and 8) .
Interestingly, when we compared the ability of A3G WT and Phe-A3G to inhibit HIV-1Δvif infection, we showed that similar expression levels of these proteins did not result in a similar reduction of viral infectivity (Fig. 5E, upper panel) . In fact, the ability of A3G WT to inhibit HIV-1Δvif infection was more than 2-fold higher than that of Phe-A3G, regardless of a similar expression. These results suggest that differences of the different constructs to inhibit viral infection were the result of the half-life of each protein, and not an artefact caused by differences in protein expression. Nevertheless, since deamination assays for each X-A3G construct were only performed qualitatively, one cannot exclude that alterations in activity of X-A3G can influence viral infectivity. Therefore, caution should be taken in consideration when interpreting these results.
Furthermore, real-time PCR analysis detected the presence of A3G mRNA transcripts in equal amounts in all the samples used for the production of HIV-1Δvif viral stocks. This result confirmed that the differences observed in A3G expression (Fig. 5C) were not caused by differences in A3G transcription efficiency (Fig. 6 ), but instead were the result of the half-life of each protein.
Discussion
In this work we investigated the relationship between A3G halflife and its antiviral activity. Assessing the time required for A3G incorporation into virions is important for determining how promptly Vif must act to induce its degradation and how long A3G must exist in the cytoplasm to be recruited to viral particles. To achieve this goal, we employed an ubiquitin-fusion strategy which allowed us to express A3G proteins with different half-lives that differed from more than 4 h (Met-A3G and Gly-A3G) to less than 5 min (Leu-A3G). In addition, this strategy can assess both the time required for A3G incorporation into virions and its antiviral activity. Consequently, it is possible to maintain A3G with a similar half-life in the cell and evaluate its phenotype.
It has been previously shown that the intracellular half-life of A3G WT can be reduced from the original 8 h to 1-2 min when expressed in the presence of Vif (Marin et al., 2003) . By using this strategy, we obtained an efficient control of A3G intracellular concentration to a level similar to that observed in the presence of the viral protein. Thus, we determined that by changing the first amino acid residue of A3G we were able to destabilize A3G and mimic the effect of Vif on A3G steady-state, which permits monitoring the antiviral activity of A3G in a Vif-free environment.
Ours results showed that A3G incorporation into virions occurs shortly after its synthesis (t1/2 = 13 min) (Fig. 5C, lane 7) and the quantity of incorporated protein increases from 13 to 85 min (Figs. 5C,  D) . Interestingly, after 85 min the quantity of protein present into virions remains similar for the different constructs (Figs. 5C, D) . This observation is in accordance with a previous work, showing the preferential recruitment of A3G into HIV-1 virions within 1.5 h after its synthesis (Soros et al. 2007) .
When the antiviral properties of A3G variants were assayed, we observed a lack of correlation between the amount protein present into virions and their antiviral activity. Incorporation of Arg-A3G (t1/ 2 = 28 min) into virions was significantly higher than Phe-A3G (t1/ 2 = 13 min) (p b 0.05), but an increase in the antiviral effect was not observed (p N 0.05). Furthermore, when similar comparison is made between Arg-A3G (t1/2 = 28 min) and Asp-A3G (t1/2 = 65 min), the quantity of protein into virions is similar but inhibition of HIV Fig. 6 . Quantification of A3G transcripts by real-time PCR. A3G, and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were quantified by real-time PCR using SYBR Green (Invitrogen) and according to the manufacturer's instructions. The ratio of A3G transcripts as normalized to GAPDH is shown. Total RNA was extracted from 293T cells transfected with A3G in the presence of pNL4.3Δvif. cDNA products were analyzed by real-time PCR using specific primers. Quantification of A3G transcripts was performed after normalization to GAPDH transcripts. Quantification of mRNA levels showed that these variations observed were not significant (p N 0.05). (A3G SD = 0.928, GAPDH SD = 1.201).
infectivity was only observed in the presence of Asp-A3G (p b 0.05). According to these results, there is a time lapse between A3G incorporation into virions and its ability to inhibit HIV infection. We may conclude that the presence of A3G into virions is not sufficient to inhibit HIV infection.
It has been proposed that incorporation of A3G into virions involves both viral and nonviral RNAs (Svarovskaia et al., 2004 , Khan et al., 2007 . While there is increasing evidence that binding to RNA is important for A3G incorporation into viral particles, we show here that A3G can be incorporated into virions without having an antiviral effect on HIV-1 infection (Fig. 5) . Furthermore, there is an increasing concern that the discrepant results on the role of RNA in A3G packaging could be due to relative differences in protein expression (Strebel and Khan, 2008) . In our study, however, we were able to control the intracellular concentration of A3G by manipulating its intracellular half-life. We showed that antiviral activity is only achieved for those A3G variants with a half-life longer than 65 min. It is possible that A3G antiviral effect may also be dependent on the encapsidation of cellular or viral RNAs that are not readily available at earlier stages (t1/2 = 13 min and t1/2 = 28 min). Although this is a tantalizing hypothesis due to our Phe-A3G results compared with A3G wt, the deaminase activity of each protein was only determined qualitatively (Supplementary data). Hence, we cannot exclude the possibility that differences in Phe-A3G and A3G wt deaminase activity may be important in viral infectivity. Moreover, deaminase-independent antiviral activities were not assessed in this report. Therefore, one cannot rule out this variable as a possible source for differences in antiviral activity seen in our assays. More studies need to be conducted to evaluate if proposed endogenous helper factors of A3G can also be incorporated into virions at later stages of viral assembly (Han et al., 2008) .
It has been shown that fusion of UBA2 to A3G could potentially be used to antagonize Vif-mediated degradation of A3G by preventing polyubiquitination (Li et al., 2008) . These authors wisely decided to stabilize A3G reaching a stronger inhibitory effect on HIV-1 infectivity (Li et al., 2008) . However, care must be taken when attempting to upregulate A3G expression as A3G mRNA is highly expressed in some tumor cells (Jarmuz et al., 2002) . Therefore, based on our results, we suggest that destabilization of A3G to a level where it can still inhibit HIV infection similar to wild-type protein without any deleterious effect on the cell physiology would be a better approach.
Materials and methods
Plasmids and DNA constructs
The full-length molecular clone of HIV-1 (pNL4.3) was obtained from the NIH AIDS Research and Reference Reagent Program (Cat. # 114), and was used for the production of infectious virus. Vif-defective molecular clone pNL4.3Δvif (Karczewski and Strebel, 1996) was used for the production of Vif-defective HIV-1 virus. pcDNA3.1-APOBEC3G-HA (A3G) was used for the expression of C-terminally epitope-tagged human A3G proteins and was kindly supplied by Dr. Klaus Strebel. pcDNA-Vif was obtained from the NIH AIDS Research and Reference Reagent Program (Kao et al., 2003) . pEGFP⁎IRES-Ub-X (Mulder and Muesing, 2000) vector was kindly supplied by Dr. Muesing and was used for the subsequent cloning steps. For the insertion of A3G downstream of the pEGFP⁎IRES-Ub-X sequence, A3G was amplified by PCR using oligos: 5′-GAG GAG GAG GCG GGG CCC AGG CGG CCA TGA AGC CTC ACT TCA GAA CAC AGT G-3′ and 5′-GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CGT TTT CCT GAT TCT GGA GAA TGG C-3′, containing the restriction site for SfiI and ligated to the cloning vector linearized by restriction digestion with SfiI. The resultant ligation originated a bicistronic A3G expression vector, where transcription of the mRNA is initiated at the cytomegalovirus promoter/ enhancer upstream of the EGFP coding sequence, along with an internal ribosome entry site (IRES) upstream of the Ub-X-A3G gene segment. Seven different amino acid sequences coding for, Met, Gly, Asn, Asp, Arg, Phe, and Leu, were introduced downstream of the Ub sequence by site directed mutagenesis using the Quick Change™ Sitedirected Mutagenesis Kit (Stratagene) as described by the manufacturer. All constructs were subjected to sequence analysis for detection of undesirable mutations.
Cell culture and transfections
Human embryonic kidney (HEK) 293T and P4 cell lines (HeLa-CD4 LTR-LacZ) were obtained from the NIH AIDS Research and Reference Reagent Program Catalog and grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal calf serum, 1× penicillinstreptomycin-fungizone mixture and L-Glutamine (Bio Whittaker). For transfections, 293T cells were grown in 6-well or 60-mm plates to nearly 70% confluent, as appropriate. Cells were transfected using the calcium phosphate precipitation method. A total of 1 to 10 μg of plasmid DNA was used for transfections in 6-well or 60-mm plates, unless stated. To generate VSV-G-pseudotyped virions, 293T cells were cotransfected with a plasmid expressing the VSV-G envelope. Total amounts of transfected DNA were kept constant in all transfections by adding empty-vector DNA (pcDNA 3.1) (Invitrogen), when appropriate. Cells were harvested typically 40-44 h post-transfection. Proteasome inhibitor MG-132 (10 mM in DMSO) was purchased from Calbiochem (Cat. # 474790). Cycloheximide was purchased from Aldrich (cat. C1988-1G) and stock solution was prepared in DMSO. Cell Proliferation Reagent WST-1 was purchased from ROCHE (Cat. # 11644807001).
Virus production and infectivity assays
Virus stocks were prepared by transfection of 293T cells with pNL4.3 or pNL4.3Δvif in the presence of wild-type A3G-HA or pEGFP-IRES-Ub-X-APOBEC3GHA, as appropriate. Virus-containing supernatants were harvested 40 to 44 h after transfection. Centrifugation removed cellular debris (3 min, 3000 ×g), and non-concentrated clarified supernatants were used for infectivity assays in P4 cells. For immunoblot analysis of viral proteins, virus-containing supernatants (2 ml) were concentrated by ultracentrifugation through 1 ml of 20% sucrose in phosphate-buffered saline (PBS) as described previously (Kao et al., 2003) .
To determine viral infectivity, viral stocks were normalized for equal p24 concentration, detected using the AIDS Vaccine Program HIV-1 p24 CA Antigen Capture Assay Kit, and used to infect 1.5 × 10 4 HeLa P4 cells in a 96-well plate in a total volume of 200 μl. HeLa P4 cells contain β-galactosidase indicator gene under the control of pNL4.3 long terminal repeat. Quantification of the β-galactosidase activity was performed in cell lysates forty-eight hours after infection, using a colorimetric assay based on the cleavage of chlorophenolred-β-D-galactopyranoside (CPRG) by β-galactosidase (Roche) (Eustice et al., 1991) . Briefly, P4 cells were placed in 100 μl of lysis buffer (MgCl 2 5 mM, NP40 0.1% in phosphate-buffered saline) and after 30 min on ice cell lysates were incubated with 100 μl of reaction buffer (CPRG 6 mM in lysis buffer) between 5 min and 2 h at 37°C.
Antisera
For detection of APOBEC3G HA-tagged, an anti-HA HRP monoclonal antibody (Roche) was used. Detection of EGFP protein was performed with anti-EGFP mouse monoclonal antibody (Roche). The HIV-1 capsid p24 protein was detected using the anti-p24 antimouse supplied by the NIH AIDS Research and Reference Reagent Program (Cat. # 530). GAPDH was used as a loading control and the antibody used was purchased from Santa-Cruz Biotechnology (GAPDH 6C5).
Immunoblotting
For detection of intracellular proteins, whole-cell-lysates were prepared as follows. Transfected 293T cells were washed once with warm phosphate-buffered saline (PBS) and re-suspended in RIPA supplemented with 0.1% of Triton X-100 and protease inhibitor cocktail EDTA-free (Roche) (500 μl/10 6 cells). Total RNA extraction and qRT-PCR Total RNA was extracted from transfected 293T cells using Trizol reagent (Invitrogen) following manufacturer's instructions. cDNA products were synthesized from RNA isolated from 2 × 10 6 cells, using random hexamers and Superscript II RNA polymerase (Invitrogen). A3G mRNA levels were quantified using SYBR Green (Invitrogen) according to the manufacturer's instructions. The primers used for the amplification of the different A3G constructs were as follows: A3G forward primer: 5′-GGC TCC ACA TAA ACA CGG TTT C-3′ (nucleotides 735 to 756); A3G reverse primer: 5′-AAG GGA ATC ACG TCC AGG AA-3′ (nucleotides 803 to 784). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a normalizing control with the following primers: forward, 5′-GGT GGT CTC CTC TGA CTT CAA CA-3′; reverse, 5′-GTT GCT GTA GCC AAA TTC GTT GT-3′. Each SYBR Green reaction contained 12.5 μl 2× SYBR Green PCR mix (Invitrogen), 0.25 μl of each 10 μM primer, and 1 μl of 1:4-diluted cDNA products. Absolute mRNA copy numbers were calculated by generating standard curves generated by serial dilutions of a plasmid containing the APOBEC3G gene and the cDNA product (GAPDH). Each sample was run in triplicate in an ABI 7000 (Applied Biosystems) with one cycle at 50°C (2 min) followed by 95°C (10 min) and 40 at 95°C (15 s) followed by 60°C (1 min) (Cho et al., 2006) .
Degradation rate quantitation
For quantification of the degradation rate of each Ub-X-A3GHA mutants, 293T cells were transfected in a 60 mm plate with 10 μg of plasmid DNA encoding the different A3G mutants. 16-20 h after transfection, cells were split in 6-well plates and treated next day were with 100 μg/ml of cycloheximide for 0, 1, 2, 3, and 4 h for A3G WT, UbMet-A3G, and Ub-Gly-A3G transfections; 0, 1, 2, and 3 h for Ub-Asn-A3G and Ub-Asp-A3G transfections; 0, 20, 40, and 60 min for Ub-Arg-A3G transfection, and 0, 5, 10, and 20 min for Ub-Leu-A3G transfection. For each sample, cellular lysates were obtained and protein content analyzed by Western blot using appropriate antibodies (as described above). Quantification of band density was performed using Quantity One 4.6.3 software (Bio-Rad Laboratories, USA).
Determination of A3G deaminase activity A3G deaminase activity was determined in an in vitro quantitative assay as described by Nowarski et al. (2008) . This is based on PCR amplification of a synthetic ss-deoxyoligonucleotide harboring the 5′ CCCA 3′ target sequence for A3G deamination as substrate. A3G WT and Ub-X-A3G mutants were expressed in 293T cells following transfection with 10 μg of plasmid DNA, as previously described. Immunoprecipitation and purification of HA-tagged A3G proteins were performed by incubation of crude lysates with anti-HA High Affinity Matrix (Roche), according to the manufacturer's instructions. Purified A3G proteins were treated with DNAse I (Invitrogen) before incubation with a deamination substrate according to the manufacturer's instructions. Purified protein (40 fmol/μl) was incubated with a ss-deoxyoligonucleotide substrate (10 fmol/μl) in the presence of 40 μM RNAse A, 25 mM Tris buffer and 0.1 mg/ml BSA for 30 min at 37°C. After incubation, resultant products of deamination reaction were amplified by PCR and subsequently digested with Eco147I. Briefly, one round of PCR was performed at 94°C (3 min) followed by fifteen rounds at 94°C (30 s) and 61°C (30 s). Restriction-reaction products were loaded onto 14% gels and separated by PAGE. Gels were stained with SYBR gold nucleic acid stain (Molecular Probes) diluted 1:10,000 in 0.5 Tris-Borate-EDTA buffer (TBE, pH 7.8), visualized by UV light (312 nm). Optical density scans was performed using Quantity One 4.6.3 software (Bio-Rad Laboratories, USA).
